
A Route to Adopting Biosimilars



Based on the experience at a major health care institution. The adoption process and roles may vary by institution.





Once a biosimilar has been implemented, a system should be established to measure the quality of the health care professional and patient experience, the utilization of the biosimilar, and the impact of biosimilar adoption on the organization as a whole.

 Regularly reporting (eg, quarterly) to department chairs, the hospital administration, and the organization's pharmacy and therapeutics committee

Possible reporting data

Access and reimbursement issues
Drug use evaluations

Adverse drug reactions
Efficacy and patient outcomes

Overall patient experience
Conversion rate
Inventory control
Stocking of new product
Handling of mixed inventory

As the health care landscape continues to change, consider whether adopting biosimilars presents an opportunity for your organization.

Organon does not guarantee that your use of this information will help you achieve your biosimilars goals. This educational resource was prepared in consultation with, and with the permission of, a health care administrator at a major health care institution who had successfully implemented a biosimilars switch within their organization.

- ORGANON

 $\ensuremath{\mathbb{C}}$ 2021 Organon group of companies. All rights reserved. US-SBT-115131 07/21